Loratadine for Bone Pain in Multiple Myeloma
Trial Summary
What is the purpose of this trial?
This trial studies if loratadine, an allergy medicine, can reduce bone pain in multiple myeloma patients who are collecting stem cells. These patients often experience pain from a drug called filgrastim, and loratadine might help ease this pain. Loratadine has been considered for managing bone pain induced by certain medications.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot be on a therapeutic dose of aspirin (more than 81 mg) within 7 days before starting the study.
Is loratadine safe for humans?
Loratadine, also known as Claritin, has been evaluated for safety in various conditions like allergic rhinitis, hay fever, and chronic idiopathic urticaria. Studies show it is generally well-tolerated, with no significant sedative or anticholinergic (dry mouth) side effects compared to placebo.12345
How does the drug loratadine differ from other treatments for bone pain in multiple myeloma?
Loratadine is unique because it is primarily an antihistamine used for allergies, but it is being explored for bone pain in multiple myeloma, which is not a typical use for antihistamines. Its potential advantage is that it is non-sedating and has a fast onset of action, which might offer relief without the drowsiness associated with other pain medications.15678
Research Team
Mansi R. Shah, MD
Principal Investigator
Rutgers Cancer Institute of New Jersey
Eligibility Criteria
This trial is for people with multiple myeloma who can consent, swallow pills, and belong to any ethnic group. It's not for non-English speakers, those allergic to study drugs or similar compounds, on high-dose aspirin recently, or having conditions that could limit full participation.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive loratadine or placebo starting 5 days before the first dose of filgrastim and continue until 5 days after completion of stem cell mobilization
Follow-up
Participants are monitored for changes in pain levels and safety after treatment
Treatment Details
Interventions
- Loratadine
Loratadine is already approved in United States, European Union, Canada for the following indications:
- Allergic rhinitis
- Urticaria
- Allergic rhinitis
- Urticaria
- Allergic rhinitis
- Urticaria
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor
National Cancer Institute (NCI)
Collaborator